ArticleFrontiers in oncology2025
Gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric metastasis of breast cancer is rare, and clinical data on its treatment and prognosis are limited at present. Herein, we report a case of gastric metastasis arising from invasive ductal and mucinous carcinoma of the breast and review the literature. A 51-year-old woman was diagnosed with infiltrating and mucinous carcinoma of the right breast accompanied by ipsilateral axillary lymph node and subclavian lymph node metastases. The molecular subtype was luminal A, and the clinical stage was T4bN3M0. The patient first received 5 cycles of neoadjuvant chemotherapy, and the treatment efficacy was stable. After 3 months of treatment with abemaciclib combined with exemestane, the tumors did not significantly reduce in size. The patient underwent surgery on February 23, 2023. The postoperative pathological examination revealed Miller Payne system grade 3 (G3). Cancer metastasis (14/20) was observed in the axillary lymph nodes, and the immunohistochemical results were as follows: ER (++, 90%), PR (+, 2%), HER-2 (3+), and Ki-67 (20%). The adjuvant therapy used was exemestane combined with trastuzumab and pertuzumab. Gastric metastasis was observed 10 months after surgery. The pathological examination revealed focal atypical cell nests with disordered arrangements, indicating malignant lesions (cancer). The immunohistochemical results were as follows: GATA3 (+), ER (++, 90%), PR (-), and HER-2 (1+). In the late stage, first-line treatment with dalpiciclib and fulvestrant was administered, and liver metastasis occurred 10 months thereafter. T-DXd treatment was subsequently administered, and the patient is currently undergoing clinical follow-up. This case highlights the possibility of gastric metastasis when gastrointestinal symptoms occur in patients with a history of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.